| Inflammatory bowel disease: clinical aspects and treatments M Fakhoury, R Negrulj, A Mooranian, H Al-Salami Journal of inflammation research, 113-120, 2014 | 576 | 2014 |
| Blood-brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insulin resistant mouse model: an implication for causal link R Takechi, V Lam, E Brook, C Giles, N Fimognari, A Mooranian, ... Frontiers in aging neuroscience 9, 399, 2017 | 134 | 2017 |
| Molecular mechanism of action and pharmacokinetic properties of methotrexate V Maksimovic, Z Pavlovic-Popovic, S Vukmirovic, J Cvejic, A Mooranian, ... Molecular biology reports 47, 4699-4708, 2020 | 89 | 2020 |
| Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, TK Mukkur, ... Drug design, development and therapy, 1221-1230, 2014 | 77 | 2014 |
| Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of … A Mooranian, R Negrulj, S Mathavan, J Martinez, J Sciarretta, ... Journal of Pharmaceutical Innovation 9, 150-157, 2014 | 73 | 2014 |
| An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations A Mooranian, R Negrulj, S Mathavan, J Martinez, J Sciarretta, ... Pharmaceutical development and technology 20 (6), 702-709, 2015 | 67 | 2015 |
| Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells A Mooranian, R Negrulj, F Arfuso, H Al-Salami Artificial cells, nanomedicine, and biotechnology 44 (1), 194-200, 2016 | 62 | 2016 |
| Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system R Negrulj, A Mooranian, H Al-Salami Journal of Endocrinology and Diabetes Mellitus 1, 49-59, 2013 | 60 | 2013 |
| Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes R Negrulj, A Mooranian, N Chen-Tan, HS Al-Sallami, M Mikov, ... Artificial cells, nanomedicine, and biotechnology 44 (5), 1290-1297, 2016 | 59 | 2016 |
| The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a … A Mooranian, R Negrulj, F Arfuso, H Al-Salami Drug delivery and translational research 5, 511-522, 2015 | 58 | 2015 |
| An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer A Mooranian, R Negrulj, N Chen-Tan, GF Watts, F Arfuso, H Al-Salami Drug design, development and therapy, 1673-1683, 2014 | 57 | 2014 |
| Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, T Mukkur, ... Drug design, development and therapy, 1003-1012, 2014 | 56 | 2014 |
| Advanced bile acid-based multi-compartmental microencapsulated pancreatic β-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment A Mooranian, R Negrulj, N Chen-Tan, M Fakhoury, F Arfuso, F Jones, ... Artificial cells, nanomedicine, and biotechnology 44 (2), 588-595, 2016 | 55 | 2016 |
| Designing anti‐diabetic β‐cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis A Mooranian, R Negrulj, H Al‐Salami, G Morahan, E Jamieson Biotechnology progress 32 (2), 501-509, 2016 | 53 | 2016 |
| Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes A Mooranian, R Negrulj, HS Al-Sallami, Z Fang, M Mikov, ... Aaps Pharmscitech 16, 45-52, 2015 | 53 | 2015 |
| Novel chenodeoxycholic acid–sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study A Mooranian, R Negrulj, M Mikov, S Golocorbin-Kon, F Arfuso, ... Journal of microencapsulation 32 (6), 589-597, 2015 | 52 | 2015 |
| Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a … A Mooranian, R Negrulj, F Arfuso, H Al-Salami Artificial cells, nanomedicine, and biotechnology 44 (7), 1642-1653, 2016 | 51 | 2016 |
| Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet JCL Mamo, V Lam, E Brook, A Mooranian, H Al-Salami, N Fimognari, ... Diabetes and Vascular Disease Research 16 (1), 87-97, 2019 | 48 | 2019 |
| Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study A Mooranian, S Raj Wagle, B Kovacevic, R Takechi, J Mamo, V Lam, ... Scientific Reports 10 (1), 106, 2020 | 47 | 2020 |
| Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment A Mooranian, R Negrulj, HS Al-Sallami, Z Fang, M Mikov, ... Journal of microencapsulation 32 (2), 151-156, 2015 | 47 | 2015 |
Hani Al-SalamiBiotechnology and Drug Development Research Laboratory, Curtin Medical School and CHIRI, CurtinVerified email at curtin.edu.au
